Last reviewed · How we verify
TNF antagonist — Competitive Intelligence Brief
marketed
TNF antagonist
TNF-α (Tumor Necrosis Factor-alpha)
Immunology
Small molecule
Live · refreshed every 30 min
Target snapshot
TNF antagonist (TNF antagonist) — Brigham and Women's Hospital. TNF antagonists block tumor necrosis factor (TNF), a key inflammatory cytokine that drives immune-mediated inflammation.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| TNF antagonist TARGET | TNF antagonist | Brigham and Women's Hospital | marketed | TNF antagonist | TNF-α (Tumor Necrosis Factor-alpha) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (TNF antagonist class)
- Brigham and Women's Hospital · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- TNF antagonist CI watch — RSS
- TNF antagonist CI watch — Atom
- TNF antagonist CI watch — JSON
- TNF antagonist alone — RSS
- Whole TNF antagonist class — RSS
Cite this brief
Drug Landscape (2026). TNF antagonist — Competitive Intelligence Brief. https://druglandscape.com/ci/tnf-antagonist. Accessed 2026-06-09.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing